The estimated Net Worth of Jon S Saxe is at least 3.03 百万$ dollars as of 19 March 2021. Mr. Saxe owns over 2,500 units of Vistagen Therapeutics stock worth over 18,116$ and over the last 21 years he sold VTGN stock worth over 2,853,240$. In addition, he makes 153,847$ as Independent Chairman of the Board at Vistagen Therapeutics.
Jon has made over 41 trades of the Vistagen Therapeutics stock since 2004, according to the Form 4 filled with the SEC. Most recently he exercised 2,500 units of VTGN stock worth 3,750$ on 19 March 2021.
The largest trade he's ever made was exercising 120,000 units of Vistagen Therapeutics stock on 9 April 2008 worth over 510,000$. On average, Jon trades about 9,268 units every 67 days since 2003. As of 19 March 2021 he still owns at least 5,751 units of Vistagen Therapeutics stock.
You can see the complete history of Mr. Saxe stock trades at the bottom of the page.
Jon S. Saxe J.D. serves as Independent Chairman of the Board of the Company. He has served as Chairman of our Board since 2000, first as Chairman of the Board of Directors of VistaGen California, then as Chairman of our Board after completion of the Merger. He also serves as the Chairman of our Audit Committee. Mr. Saxe is the retired President and was a director of PDL BioPharma from 1989 to 2008. From 1989 to 1993, he was President, Chief Executive Officer and a director of Synergen, Inc. (acquired by Amgen). Mr. Saxe served as Vice President, Licensing & Corporate Development for Hoffmann-Roche from 1984 through 1989, and Head of Patent Law for Hoffmann-Roche from 1978 through 1989. Mr. Saxe currently is a director of Durect Corporation (NASDAQ: DRRX), and six private life science companies, Achelios, Arbor Vita Corporation, Aether, Inc., Arcuo Medical, LLC, Cancer Prevention Pharmaceuticals, Inc., Trellis Bioscience, Inc. and Epalex Corporation. Mr. Saxe has also served as a director of other biotechnology and pharmaceutical companies, including ID Biomedical (acquired by GlaxoSmithKline), Sciele Pharmaceuticals, Inc. (acquired by Shionogi), Amalyte (acquired by Kemin Industries), Cell Pathways (acquired by OSI Pharmaceuticals), Lumos Pharma, Inc. (merged with New Link Genetics) and other companies, both public and private. Mr. Saxe has a B.S.Ch.E. from Carnegie-Mellon University, a J.D. degree from George Washington University and an LL.M. degree from New York University.
As the Independent Chairman of the Board of Vistagen Therapeutics, the total compensation of Jon Saxe at Vistagen Therapeutics is 153,847$. There are 9 executives at Vistagen Therapeutics getting paid more, with Shawn Singh having the highest compensation of 933,667$.
Jon Saxe is 84, he's been the Independent Chairman of the Board of Vistagen Therapeutics since 2011. There are no older and 15 younger executives at Vistagen Therapeutics.
Jon's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over 147,300$ worth of Vistagen Therapeutics stock and bought 1,944,506 units worth 18,208,989$ . The most active insiders traders include Healthcare Capital Partners...、Capital Lp Commodore、Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of 378,372$. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth 17,958,751$.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: